A phase 3, randomized, open-label study to compare the efficacy of tislelizumab (BGB-A317) versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

Lin Shen,Jaffer A. Ajani,Sung-Bae Kim,Eric Van Cutsem,Baohong Guo,James Song,Virginia E. Paton,Ken Kato

A phase 3, randomized, open-label study to compare the efficacy of tislelizumab (BGB-A317) versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

2018

Lin Shen
Jaffer A. Ajani
Sung-Bae Kim
Eric Van Cutsem
Baohong Guo
James Song
Virginia E. Paton
Ken Kato

TPS3111Background: Approximately 40% of patients (pts) with esophageal cancer are diagnosed with advanced unresectable or metastatic disease; the 5-year survival rate for advanced disease is < 5%. ...

Keywords:

Second-line therapy
Oncology
Pathology
Medicine
Internal medicine
Metastatic Esophageal Squamous Cell Carcinoma
Chemotherapy
advanced disease
Survival rate
Esophageal cancer
open label study
Disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations